Gain Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Gain Therapeutics

07/08/2026 17:28

Gain Therapeutics Inc GANX.OQ GANX.O is expected to  show no change in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Gain Therapeutics Inc is for a loss of 14 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Gain Therapeutics Inc is $8.00, about 349.4% above its last closing price of $1.78
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.14
-0.14
-0.13
Beat
5.5
Dec. 31 2026
-0.14
-0.14
-0.11
Beat
24.1
Sep. 30 2025
-0.16
-0.15
-0.15
Met
0​
Jun. 30 2025
-0.17
-0.17
-0.19
Missed
-12.9
​​Mar. 31 2025
-0.18
-0.18
-0.16
Beat
11.1
Dec. 31 2024
-0.17
-0.18
-0.11
Beat
40​
Sep. 30 2024
-0.22
-0.21
-0.17
Beat
20.9
Jun. 30 2024
-0.19
-0.20
-0.42
Missed
-110
This summary was machine generated August 7 at 16:28 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)